# US 2003/0216635 A1 · Method and system for monitoring pancreatic pathologies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216635 A1
- Document ID: US20030216635A1
- Status: Published application
- Kind: A1
- Application number: 10/169,466
- Filed: 2003-04-03
- Published: 2003-11-20
- Earliest claimed: 2000-01-06
- Inventors: Irun R Cohen; Hadassa Degani; Lior Bruker; Raanan Margalit
- Web page: https://patentgrep.com/patent/US20030216635A1

## CPC

- G01R 33/5601: {involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/416: {the spleen}
- A61B 5/425: {pancreas}
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A method for non invasively detecting and monitoring pancreatic pathologies preferably related to vascular changes or inflammatory processes in the pancreas, such as the onset of IDDM, by magnetic resonance imaging (MRI) is disclosed. The method enables the detection of IDDM prior to the appearance of clinical manifestation, by detecting early stages of IDDM such as insulitis. The disclosed method also enables correlation of different stages of pancreatic diseases with the characteristics of contrast enhancement curves. A MRI system for monitoring pancreatic pathology in a patient is also disclosed. the system comprises a single volume coil for transmitting and receiving signals from an internal body organ of a patient, such as the pancreas, or the spleen.

## Claims

### Claim 1

A method for monitoring a pancreatic pathology in a patient comprising the steps of:
obtaining a first magnetic resonance image of an internal body organ using defined sequence parameters;
injecting a contrast agent to the patient;
obtaining a plurality of subsequent contrast enhancement images of the internal body organ using the defined sequence parameters;
creating an intensity curve, by plotting intensity over time, from the plurality of subsequent contrast enhancement images;
converting the intensity curve to an enhancement curve, said enhancement curve having a linear portion and a plateau portion;
extracting an enhancement value at plateau from the enhancement curve; and comparing the enhancement value at plateau to a standard, thereby monitoring the pancreatic pathology in the patient.

### Claim 2 (depends on 1)

The method according to claim 1 further comprising the step of obtaining an axial image of the internal body organ prior to the step of obtaining a first magnetic resonance image, said axial image having defined alignment parameters, and wherein the step of obtaining a first magnetic resonance image and the step of obtaining a plurality of subsequent contrast enhancement images are preformed by using the defined alignment parameters.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the internal body organ is the pancreas.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the internal body organ is the spleen.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the step of injecting a contrast agent is preformed by IV injection of the contrast agent to the patient.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the contrast agent does not intersect cell membranes.

### Claim 7 (depends on 6)

The method according to claim 6 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the pancreatic pathology is accompanied by changes in vascularity of the pancreas.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the pancreatic pathology is IDDM.

### Claim 10 (depends on 2)

The method according to claim 2 wherein the step of obtaining an axial image of the internal body organ comprises the steps of:
applying to the internal body organ a fat suppression pulse having a determined pulse offset frequency and a determined bandwidth; and
obtaining a T1 gradient echo image of the internal body organ.

### Claim 11 (depends on 2)

The method according to claim 2 wherein the internal body organ is the pancreas.

### Claim 12 (depends on 2)

The method according to claim 2 wherein the internal body organ is the spleen.

### Claim 13 (depends on 2)

The method according to claim 2 wherein the contrast agent does not intersect cell membranes.

### Claim 14 (depends on 13)

The method according to claim 13 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 15 (depends on 2)

The method according to claim 2 wherein the pancreatic pathology is accompanied by changes in vascularity of the pancreas.

### Claim 16 (depends on 2)

The method according to claim 2 wherein the pancreatic pathology is IDDM.

### Claim 17 (depends on 1)

The method according to claim 1 wherein a large portion of the plurality of subsequent contrast enhancement images is obtained at a time correlating to the plateau portion of the enhancement curve.

### Claim 18

A method for monitoring a pancreatic pathology in a patient comprising the steps of:
obtaining a first magnetic resonance image of an internal body organ using defined sequence parameters;
injecting a contrast agent to the patient;
obtaining a plurality of subsequent contrast enhancement images of the internal body organ using the defined sequence parameters;
creating an intensity curve, by plotting intensity over time, from the plurality of subsequent contrast enhancement images;
converting the intensity curve to an enhancement curve, said enhancement curve having a linear portion and a plateau portion;
extracting an initial rate value of the enhancement curve; and
comparing the initial rate value to a standard, thereby monitoring the pancreatic pathology in the patient.

### Claim 19 (depends on 18)

The method according to claim 18 further comprising the step of obtaining an axial image of the internal body organ prior to the step of obtaining a first magnetic resonance image, said axial image having defined alignment parameters, and wherein the step of obtaining a first magnetic resonance image and the step of obtaining a plurality of subsequent contrast enhancement images are preformed by using the defined alignment parameters.

### Claim 20 (depends on 18)

The method according to claim 18 wherein the internal body organ is the pancreas.

### Claim 21 (depends on 18)

The method according to claim 18 wherein the internal body organ is the spleen.

### Claim 22 (depends on 18)

The method according to claim 18 wherein the step of injecting a contrast agent is preformed by IV injection of the contrast agent to the patient.

### Claim 23 (depends on 18)

The method according to claim 18 wherein the contrast agent does not intersect cell membranes.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 25 (depends on 18)

The method according to claim 18 wherein the pancreatic pathology is accompanied by changes in vascularity of the pancreas.

### Claim 26 (depends on 18)

The method according to claim 18 wherein the pancreatic pathology is IDDM.

### Claim 27 (depends on 19)

The method according to claim 19 wherein the step of obtaining an axial image of the internal body organ comprises the steps of:
applying to the internal body organ a fat suppression pulse having a determined pulse offset frequency and a determined bandwidth; and
obtaining a T1 gradient echo image of the internal body organ.

### Claim 28 (depends on 19)

The method according to claim 19 wherein the internal body organ is the pancreas.

### Claim 29 (depends on 19)

The method according to claim 19 wherein the internal body organ is the spleen.

### Claim 30 (depends on 19)

The method according to claim 19 wherein the contrast agent does not intersect cell membranes.

### Claim 31 (depends on 30)

The method according to claim 30 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 32 (depends on 19)

The method according to claim 19 wherein the pancreatic pathology is accompanied by changes in vascularity of the pancreas.

### Claim 33 (depends on 19)

The method according to claim 19 wherein the pancreatic pathology is IDDM.

### Claim 34 (depends on 18)

The method according to claim 18 wherein a large portion of the plurality of subsequent contrast enhancement images is obtained at a time correlating to the linear portion of the enhancement curve.

### Claim 35

A method for detecting insulitis in a patient comprising the steps of:
obtaining a first magnetic resonance image of an internal body organ using defined sequence parameters;
injecting a contrast agent to the patient;
obtaining a plurality of subsequent contrast enhancement images of the internal body organ using the defined sequence parameters;
creating an intensity curve, by plotting intensity over time, from the plurality of subsequent contrast enhancement images;
converting the intensity curve to an enhancement curve, said enhancement curve having a linear portion and a plateau portion;
extracting an enhancement value at plateau from the enhancement curve; and
comparing the enhancement value at plateau to a standard, thereby obtaining information regarding the occurrence of insulitis in the patient.

### Claim 36 (depends on 35)

The method according to claim 35 further comprising the step of obtaining an axial image of the internal body organ prior to the step of obtaining a first magnetic resonance image, said axial image having defined alignment parameters, and wherein the step of obtaining a first magnetic resonance image and the step of obtaining a plurality of subsequent contrast enhancement images are preformed by using the defined alignment parameters.

### Claim 37 (depends on 35)

The method according to claim 35 wherein the internal body organ is the pancreas.

### Claim 38 (depends on 35)

The method according to claim 35 wherein the internal body organ is the spleen.

### Claim 39 (depends on 35)

The method according to claim 35 wherein the step of injecting a contrast agent is preformed by IV injection of the contrast agent to the patient.

### Claim 40 (depends on 35)

The method according to claim 35 wherein the contrast agent does not intersect cell membranes.

### Claim 41 (depends on 40)

The method according to claim 40 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 42

A method for detecting insulitis in a patient comprising the steps of:
obtaining a first magnetic resonance image of an internal body organ using defined sequence parameters;
injecting a contrast agent to the patient;
obtaining a plurality of subsequent contrast enhancement images of the internal body organ using the defined sequence parameters;
creating an intensity curve, by plotting intensity over time, from the plurality of subsequent contrast enhancement images;
converting the intensity curve to an enhancement curve, said enhancement curve having a linear portion and a plateau portion;
extracting an initial rate value of the enhancement curve; and
comparing the initial rate value to a standard, thereby monitoring the pancreatic pathology in the patient.

### Claim 43 (depends on 42)

The method according to claim 42 further comprising the step of obtaining an axial image of the internal body organ prior to the step of obtaining a first magnetic resonance image, said axial image having defined alignment parameters, and wherein the step of obtaining a first magnetic resonance image and the step of obtaining a plurality of subsequent contrast enhancement images are preformed by using the defined alignment parameters.

### Claim 44 (depends on 42)

The method according to claim 42 wherein the internal body organ is the pancreas.

### Claim 45 (depends on 42)

The method according to claim 42 wherein the internal body organ is the spleen.

### Claim 46 (depends on 42)

The method according to claim 42 wherein the step of injecting a contrast agent is preformed by IV injection of the contrast agent to the patient.

### Claim 47 (depends on 42)

The method according to claim 42 wherein the contrast agent does not intersect cell membranes.

### Claim 48 (depends on 47)

The method according to claim 47 wherein the contrast agent is gadolinium diethylenetriamine pentaacetic acid.

### Claim 49

An MRI system for monitoring a pancreatic pathology in a patient comprising a single volume coil for transmitting and receiving signals from an internal body organ selected from the group consisting of the pancreas, and the spleen.

### Claim 50 (depends on 49)

The MRI system according to claim 49 further comprising a spectrometer recording at 4.7 Tesla.
